×
Third-quarter 2026 net revenue climbed 16% year over year to a record $193.4 million , exceeding consensus estimates near $182 million. Net loss narrowed sharply to $10.4 million , or $0.09 per share , beating the analyst consensus loss of roughly $0.21 to $0.24 per share.
Revenue rose 33.9% year over year to $72.0 million, ahead of the roughly $66.6 million consensus estimate. GAAP (generally accepted accounting principles) net loss narrowed to $10.7 million, or $0.35 per share, versus a loss of $0.38 per share a year earlier.
Butterfly Network reported third quarter 2026 revenue of $32.6 million , up 52% year over year and about 9% above the top end of its own guidance. GAAP (Generally Accepted Accounting Principles) net loss narrowed to $12.8 million , or $0.05 per share, compared with a $34.0 million loss, or $0.13 per share, a year earlier.
DexCom reported third quarter 2026 revenue of $1.34 billion , up 11% year over year on both a reported and organic basis. Adjusted (non-GAAP) earnings per share came in at $0.73 , beating the analyst consensus estimate of $0.67 by roughly 8%.
Stryker reported third quarter 2026 net sales of $6.52 billion , up 7.7% year over year, but below the analyst consensus of roughly $6.62 billion. Adjusted EPS (earnings per share) came in at $3.52 , up 10.3% from a year ago, narrowly missing the $3.55 consensus estimate.
LUNG is up +20.24% during regular trading today, extending its post-earnings rally after closing at $2.52 in the prior session. The primary catalyst is a Q3 earnings beat: EPS of -$0.19 topped the -$0.26 consensus and revenue of $22.8M beat $21.9M, marking a return to year-over-year growth.
AxoGen (AXGN) shares have risen roughly 18% over the last 30 days, from a closing price near $42.44 on September 29 to about $50.22 as of late October. The advance was driven by a third-quarter earnings beat and a raised full-year 2026 revenue outlook, which sent the stock sharply higher on October 28.
LUNG is up +10.32% today, trading near $2.78 versus Wednesday's $2.52 close during the regular Nasdaq session. The move extends post-earnings momentum from Q3 2026 results (Oct 27), which beat estimates: revenue of $22.8M (+6% YoY) and a narrower $0.19 per-share loss versus the $0.26 consensus.
MaxCyte shares have climbed roughly 43% over the past 30 days, rising from about $1.18 to approximately $1.69. The move accelerated sharply on October 14 after the company reported preliminary third-quarter 2026 core revenue of about $8.1 million, up 26% year over year, and raised its full-year 2026 revenue guidance to approximately $34 million.
Glaukos (GKOS) shares climbed roughly 48% over the past 30 days, rising from about $158.55 on September 29, 2026, to approximately $234.92 intraday on October 29, 2026. The move was driven primarily by a blowout third-quarter 2026 report, with record net sales of $211 million, up 58% year over year and well above consensus estimates.
NVCR fell -9.67% to roughly $12.80, down from the prior session's close of $14.17, with selling starting in premarket trading after Q3 results. Primary catalyst: Q3 2026 earnings — the company beat estimates, but management flagged slowing U.S. momentum tied to daraxonrasib's market entry and limited access to detail Optune Pax.
Total revenue reached $12.08 million in the third quarter of 2026, up 36% from $8.86 million a year earlier. Product revenue climbed 47% to $7.89 million, while service and other revenue rose 20% to $4.18 million.
Third quarter 2026 net sales reached $211.0 million , up 58% year over year and above the roughly $168 million consensus estimate. Glaukos swung to GAAP net income of $2.0 million , or $0.03 per diluted share, compared with a loss of $16.2 million a year earlier.
Boston Scientific reported third-quarter 2026 net sales of $5.138 billion, up 1.5% year over year on a reported, operational, and organic basis, narrowly above the consensus estimate of about $5.12 billion. Adjusted earnings per share (EPS, the profit attributable to each outstanding share) came in at $0.73, down 3% from $0.75 a year earlier and slightly below the roughly $0.75 analyst consensus.
Glaukos Corporation (GKOS) shares rose roughly 14.4% over the trailing 30 days, climbing from about $158.56 on September 28, 2026, to $181.47 by October 28, 2026. The advance extends a broader rally, with the stock up approximately 19.9% over the trailing three months.
MXCT is trading up +9.74% at $1.69 during regular-session hours, extending a rally from its prior close of $1.54. The move builds on MaxCyte's Oct. 14 preliminary Q3 results: core revenue of ~$8.1M (+26% YoY) beat estimates, and FY26 revenue guidance was raised to ~$34M from $30M–$32M.
AXGN surged +28.72% during regular trading, climbing from a prior close of $37.46 to roughly $48.22 after gapping higher in the premarket. The primary catalyst was a Q3 earnings beat: revenue of $75.8M topped the $73.2M consensus, while adjusted EPS of $0.21 easily exceeded the $0.13 estimate.
Pulmonx shares rose roughly 35% over the past 30 days, climbing from about $1.96 to approximately $2.64 as of late October 2026. The rally followed third-quarter 2026 results that marked Pulmonx's first return to year-over-year global revenue growth.
Beta Bionics (BBNX) shares fell roughly 13% over the last 30 days, from about $20.52 on September 28 to near $17.78 in late October. The decline accelerated even as the company reported record third-quarter net sales of $35.5 million, up 30% year over year, as widening losses and higher operating expenses weighed on sentiment.
KIDS shares climbed roughly 23% over the last 30 days, from a closing level near $22.58 to approximately $27.75, driven largely by a strong third-quarter report. Third-quarter 2026 revenue rose 19% year over year to a record $72.7 million, and management raised full-year revenue guidance to $270–$273 million.
Previous
20 of 31
Next